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Summary
Background Changes in the geographical distribution of genetic disorders are often thought to happen slowly, 
especially when compared with infectious diseases. Whereas mutations, genetic drift, and natural selection take place 
over many generations, epidemics can spread through large populations within a few days or weeks. Nevertheless, 
population movements can interfere with these processes, and few studies have been done of their eﬀ ect on genetic 
disorders. We aimed to investigate the eﬀ ect of global migration on the distribution of the sickle-cell gene—the most 
common and clinically signiﬁ cant haemoglobin structural variant.
Methods For each country, we extracted data from the World Bank’s Global Bilateral Migration Database about 
international human migrations between 1960 and 2000. We combined this information with evidence-based 
estimates of national HbS allele frequencies, generated within a Bayesian geostatistical framework, to analyse 
temporal changes in the net numbers of migrants, and classiﬁ ed countries with an index summarising these temporal 
trends.
Findings The number of international migrants increased from 92·6 million in 1960, to 165·2 million in 2000. The 
estimated global number of migrants with HbS increased from about 1·6 million in 1960, to 3·6 million in 2000. This 
increase was largely due to an increase in the number of migrants from countries with HbS allele frequencies higher 
than 10%, from 3·1 million in 1960, to 14·2 million in 2000. Additionally, the mean number of countries of origin for 
each destination country increased from 70 (SE 46) in 1960, to 98 (48) in 2000, showing an increasing diversity in the 
network of international migrations between countries. Our index of change map shows a patchy distribution of the 
magnitude of temporal changes, with the highest positive and negative values scattered across all continents.
Interpretation Global human population movements have had a substantial eﬀ ect on the distribution of the HbS 
gene. Population movements can create a long-term burden on health-care systems. Our ﬁ ndings, which emphasise 
countries in which migration ﬂ uxes are changing the most, should increase awareness about the global burden of 
haemoglobinopathies and encourage policy makers to implement speciﬁ c public health interventions, such as 
screening programmes and genetic counselling.
Funding Wellcome Trust, European Research Council, Bill & Melinda Gates Foundation, National Institute of Allergy 
and Infectious Diseases–National Institutes of Health, the Research and Policy for Infectious Disease Dynamics 
program, Fogarty International Center.
Introduction
The mobility of human beings worldwide has reached an 
unprecedented level.1 With changes in the modes and 
speed of international transportation, constraints 
previously imposed by natural barriers and long distances 
have greatly reduced. This increasing globalisation 
means that populations previously isolated from one 
another are now linked by regular ﬂ uxes of travellers and 
migrants.2 This process has had a substantial eﬀ ect on 
public health.3–6 With increasing mobility over long 
distances, the risks of local disease outbreaks spreading 
globally have become much higher than previously, as 
shown by recent inﬂ uenza pandemics and spread of 
vector-borne diseases.7–9 International migrations can 
also have a long-term eﬀ ect on public health through the 
introduction of deleterious genes into populations in 
which they were previously absent. Because genes are 
inherited over generations, their burden can seem to 
present an indirect threat to public health, and few 
studies have focused on changes in the distribution of 
genetic disorders.10–12 However, as shown for infectious 
diseases, prevention measures based on early diagnosis 
can reduce the long-term burden of genetic disorders,13 
and regular assessment of the associated risks, on the 
basis of existing epidemiological knowledge,14 is essential.
After decades of neglect, sickle haemoglobin (HbS) is 
emerging as a major public health concern.15 HbS is a 
structural variant of normal adult haemoglobin (HbA) 
that is inherited as an autosomal recessive mendelian 
trait. Whereas individuals heterozygous for sickle 
haemoglobin (HbAS) are generally asymptomatic, most 
homozygous children (HbSS) die before the age of 5 years 
in low-income countries, and most surviving adults 
suﬀ er from lifelong acute and chronic complications in 
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high-income countries.16,17 As originally suggested by the 
so-called malaria hypothesis, the geographical 
distribution of HbS was historically driven by the 
selective advantage conferred by this gene in protecting 
against Plasmodium falciparum malaria infection in 
heterozygous individuals.18,19 HbS was therefore identiﬁ ed 
in malarious regions across sub-Saharan Africa; parts of 
the Mediterranean, including Greece and southern 
Turkey; various oases on the eastern and western coast of 
the Arabian Peninsula; and in Indian tribes in the 
southern part of Chhattisgarh and Karnataka.20–22 HbS 
was absent in Indigenous Americans, northern 
Europeans, and Oceanian populations.20–22 Distribution 
of the HbS gene expanded substantially after forced 
migration of African people to the Americas through the 
African slave trade.23 As such, HbS became relatively 
prevalent in African American populations, particularly 
in those in the USA,24 Brazil,25 and the Caribbean.26
The health burden of haemoglobinopathies, including 
sickle haemoglobin, is expected to increase in the coming 
decades.27,28 The number of individuals needing diagnosis 
and management for these disorders is increasing in 
both low-income and high-income countries. In low-
income countries, substantial improvements in 
nutrition, hygiene, and access to health care and drugs 
have led to important reductions in childhood mortality, 
which increase the chances of survival of children with 
sickle-cell anaemia, who would have previously died 
undiagnosed.29 In high-income countries, immigration 
from countries with a high HbS prevalence contribute to 
the spread of this gene into new populations, within 
which screening programmes become increasingly 
necessary.24,30 In both cases, clinicians are becoming 
increasingly likely to encounter HbS patients or carriers, 
and need to be able to provide adequate health care and 
counselling. Awareness of the disease, combined with 
eﬃ  cient prevention programmes, based on appropriate 
diagnosis and management, can help greatly in the 
reduction of long-term severe complications.17
In this study, we aimed to investigate the eﬀ ect of 
recent international population movements on the 
distribution of the sickle-cell gene. We assess the main 
migration trends and deﬁ ne countries in which the 
implementation of appropriate public health policies 
might be more urgently needed on the basis of the 
origins of migrants. Although we focus on HbS, various 
other common haemoglobin variants, including HbC, 
HbE, HbD, and a large range of α-thalassaemia and 
β-thalassaemia mutations, are also spreading globally 
because of increasing population movements, and the 
same principles as for HbS apply.
Methods
Database and data extraction
We extracted data from the World Bank’s Global 
Bilateral Migration Database.31 This database includes 
decennial matrices of migrant stocks for the 
period 1960–2000 for 232 countries. It provides a 
comprehensive picture of human migrations worldwide 
on the basis of censuses and population registry records, 
with migrant origins deﬁ ned by their country of birth. 
Various techniques were used to estimate missing data to 
provide a single and complete matrix of international 
bilateral migrant stocks.31 No measures of uncertainty 
associated with this dataset are available. We then 
combined this information with recent evidence-based 
estimates of national HbS allele frequencies (posterior 
median), with uncertainty measures (IQR), generated 
within a Bayesian geostatistical framework.32
Statistical analysis
In view of the usual clinical severity of the disease and 
shortened life expectancy of HbSS individuals, we 
assumed that migrants would have either normal 
haemoglobin (HbAA) or would be carriers of the sickle-
cell trait (HbAS). We used the Hardy-Weinberg 
equilibrium equation33,34 to estimate the level of HbS 
gene importation into each destination country, and 
calculated the estimated number of net HbAS individuals 
who had moved in and out of each country in 1960, 1970, 
1980, 1990, and 2000.
We calculated the net number of migrants and 
estimated the net number of migrants with HbS as the 
diﬀ erence between the estimated number of immigrants 
with HbS and the estimated number of emigrants with 
HbS (appendix). To enable comparison of trends in the 
estimated net number of migrants with HbS with those 
in the net number of overall migrants globally, or for a 
speciﬁ c country, we used the number of migrants at the 
start of the study period (ie, 1960) as a reference value, 
and converted values for subsequent years into percentage 
diﬀ erences. We generated temporal plots of these relative 
changes in the net number of migrants and estimated net 
number of migrants with HbS for each country 
(appendix). We then classiﬁ ed countries into seven 
classes on the basis of a combination of two factors. The 
ﬁ rst was the HbS index, which is based on the slope of a 
linear regression ﬁ tted to the net number of migrants 
with HbS. A positive slope shows an increasing burden, 
whereas a negative slope suggests a decreasing burden. If 
the slope was more than 2, the code given was +1. If the 
slope was between –2 and 2, the code given was 0, and if 
the slope was –2 or less, the code given was –1. The 
second factor was the DIV index, which categorises the 
divergence between trends in the number of net migrants 
and the estimated number of net migrants with HbS, as 
assessed by the absolute value of the ratio (termed R) or 
diﬀ erence (termed D) between the slope of the two trend 
lines, termed HbS slope and MIG slope, respectively, 
dependent on the sign of the two slopes (appendix). An 
increasing distance between the two trend lines shows a 
growing change in the relative burden of net migrants 
with HbS compared with the net ﬂ ux of overall migrants. 
If the decrease in the net number of estimated migrants 
For more on the Global Bilateral 
Migration Database see http://
data.worldbank.org/data-
catalog/global-bilateral-
migration-database
See Online for appendix
Articles
www.thelancet.com/lancetgh   Vol 2   February 2014 e82
with HbS is lower than that in the number of net 
migrants, or if the increase is higher, the burden 
will increase; conversely, if the decrease in the net number 
of migrants with HbS is greater than that in the number 
of net migrants, or if the increase is lower, the burden will 
decrease. The appendix summarises the rules used to 
deﬁ ne DIV index. We deﬁ ned cutoﬀ  values for each 
combination of slope signs with quantiles of the 
normalised distribution of R or D, whichever was 
appropriate. We used a maximum of ﬁ ve classes, from 
–2 to +2, for the DIV index. Finally, we calculated a 
summary index—the index of change—as the sum of the 
HbS and DIV indices. As such, the values of the index of 
change range between –3 and 3. The appendix shows 
values of the HbS and MIG slopes, HbS index, DIV index, 
and index of change for all countries and gives further 
details about the calculation of the index of change, with 
reference to some speciﬁ c working examples.
Maps of the estimated net number of migrants with 
HbS at the country level and the map of our overall index 
of change were created in ArcMap (version 10.1). Maps of 
ﬂ uxes to and from selected countries were generated 
with the tailored code written in R 2.15.235 (appendix) and 
implemented in ArcMap (version 10.1).
Role of the funding source
The sponsors of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for publication. 
Results
Globally, the number of international migrants increased 
from 92·6 million in 1960, to 165.2 million in 2000.1 In 
that same period, the estimated number of migrants with 
HbS increased faster than did the overall number of 
migrants, from about 1·6 million in 1960, to 3·6 million 
in 2000 (ﬁ gure 1). This ﬁ nding is due to an increase in the 
estimated number of migrants from countries with HbS 
allele frequencies higher than 10%, from 3 083 457 in 1960, 
to 14 178 197 in 2000. Alongside this increase, the mean 
number of countries of origin for each destination 
country increased from 70 (SE 46) in 1960, to 98 (48) 
in 2000, showing an increasing diversity in the network 
of international migrations between countries. This trend 
was also accompanied by an increase in the mean overall 
frequency of HbS in the countries of origin, from 1·79% 
(SE 1·30) in 1960, to 2·02% (1·12) in 2000 (ﬁ gure 2).
The maps in ﬁ gure 3 emphasise the changes in the 
eﬀ ect of international migrations on the distribution of 
HbS globally between 1960 and 2000. The estimated 
number of migrants with HbS moving to North America, 
western Europe, or Australia increased (so-called sinks of 
HbS), whereas trends in African countries, India, and 
the Middle East were towards negative net ﬂ uxes of 
migrants with HbS (so-called sources). Because of the 
size of its population, India remained one of the main 
source countries throughout the study period (ﬁ gure 3).
By analysis of the net number of overall migrants and 
the net number of migrants with HbS, relative to their 
respective levels in 1960 for each country, we could 
examine speciﬁ c trends at the national level (appendix). 
Figure 4 shows subregional variations for a subset of 
source and sink countries within each region. In Africa, 
HbS was originally common in the Democratic Republic 
of Congo (source), but was relatively rare in South 
African populations (sink). Changes in South Africa 
seem to have happened mostly in the 1990s (ﬁ gure 4). In 
the Americas, the patterns between Mexico and the USA, 
in which the HbS gene was ﬁ rst introduced via slave 
trade routes, are contrasting. In Mexico, the number of 
net migrants and estimated number of net migrants with 
HbS are both decreasing, but the number of net migrants 
Figure 1: Global trends in the number of international migrants and estimated migrants with HbS compared 
with the 1960s level
We calculated the solid red line on the basis of median HbS frequency; the light red area represents the uncertainty 
on the basis of the 25% and 75% quantiles. HbS=sickle-cell haemoglobin.
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Figure 2: Global trends in the average number of countries of origin per country of destination and the average 
estimated HbS frequency in the countries of origin per country of destination between 1960 and 2000
HbS=sickle-cell haemoglobin.
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Figure 3: Estimated net 
migrations of individuals 
with HbS at the country level 
in 1960, 1970, 1980, 1990, 
and 2000
Countries in red correspond to 
those in which the estimated 
number of immigrants with 
HbS is higher than the 
estimated number of 
emigrants with HbS (sink 
countries). Countries in blue 
correspond to those in which 
the estimated number of 
immigrants with HbS is lower 
than the estimated number of 
emigrants with HbS (source 
countries). To aid 
comparisons, the same colour 
classes were used for all maps. 
HbS=sickle-cell haemoglobin.
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is decreasing more slowly than the estimated number of 
net migrants with HbS, suggesting a decreasing burden 
in relation to migrations (ﬁ gure 4). In the USA, both 
trend lines are increasing and the number of net 
migrants with HbS is increasing faster than the overall 
net number of migrants, suggesting an increasing 
burden in relation to migrations (ﬁ gure 4). Across Asia, 
although estimated ﬂ uxes of migrants with HbS mostly 
decreased during the study period, net relative ﬂ uxes 
were positive in Pakistan (sink), but negative in India 
(source), which indicates the regions of high prevalence 
in parts of the Indian subcontinent. In Europe, western 
European countries were overall sink countries (eg, 
France and UK), whereas Mediterranean countries where 
HbS is endemic were usually source countries (eg, 
Greece; ﬁ gure 4). Patterns recorded in other countries 
varied (appendix).
Our index of change provides a summary of the main 
trends globally (appendix). This map shows a patchy 
distribution of the magnitude of temporal changes, with 
the highest positive (eg, Ecuador, Botswana, Portugal, 
and Thailand) and negative values (eg, Panama, Albania, 
Madagascar, and Iran) scattered in all continents. 
Estimated outgoing ﬂ uxes of migrants with HbS from 
Nigeria—the country with the highest burden of sickle-
cell disease—increased quantitatively between 1960 and 
Figure 4: Net numbers of migrants and estimated net number of migrants with HbS (based on the posterior median) relative to the 1960 level for selected 
countries in Africa (A), the Americas (B), Asia (C), and Europe (D), between 1960 and 2000
Countries on the left-hand side tend to be sinks of migrants with HbS (ie, positive values along the y-axis); countries on the right-hand side tend to be sources of 
migrants with HbS (ie, negative values along the y-axis). Uncertainties (based on the IQR) associated with the trends in migrants with HbS are shown in light red. The 
appendix shows plots for all countries. HbS=sickle-cell haemoglobin.
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2000, and there was diversiﬁ cation in their destinations 
(ﬁ gure 5). Similar trends were shown in assessment of 
estimated incoming ﬂ uxes of migrants with HbS to the 
USA and the UK—two sink countries, both of which 
have implemented screening programmes for sickle-cell 
disorders (ﬁ gure 6).
Discussion
Our ﬁ ndings emphasise the spread of the HbS gene 
through recent human migrations and the global 
importance of this emerging public health problem. 
Although the magnitude of the public health burden 
associated with HbS in a given country is mainly driven 
by the frequency of this gene in its native and assimilated 
populations,32 clinicians worldwide should be aware that 
the possibility of encountering a patient with symptoms 
associated with sickling disorders is increasing.36–42 Our 
summary map (appendix) draws attention to countries in 
which these changes are happening, and therefore, to 
those where a focus on awareness and prevention, 
through the introduction or enhancement of screening 
programmes, should become a priority.13 The USA and 
UK have both implemented universal newborn screening 
programmes,30,43,44 but screening of immigrants is less 
systematic. Various European countries, including the 
Netherlands,45 France,46 Greece,47 and Cyprus,48 have 
implemented registries for haemoglobinopathies, but 
integration of immigrant patients to those speciﬁ c 
health-care services is still often diﬃ  cult.10,49 In Africa, 
large-scale screening programmes are still uncommon.
In the absence of a curative treatment for sickle-cell 
disorders,50 and in view of the huge lifetime costs 
associated with the treatment of patients with these 
disorders,51 education, planning policies, and prevention 
programmes are essential strategies to reduce the 
subsequent long-term economic and health burden.27–29 
Rather than suggesting strict immigration policies, our 
ﬁ ndings emphasise the need for an international 
approach to prevent such genetic health disorders 
globally. Although WHO recognised sickle-cell disease as 
a global public health problem in 2006,15 and a resolution 
on the prevention and management of birth defects, 
including sickle-cell disease and the thalassaemias, was 
adopted in 2010 at the 63rd World Health Assembly, little 
has changed in terms of international public health 
policies. Until such changes take place, collaborations 
between source and sink countries could be developed 
on the basis of political, cultural, religious, and linguistic 
similarities, and historical links between countries.2 For 
example, the links between the Democratic Republic of 
Congo and Belgium, or France and Algeria, are clearly 
shown in their migration patterns. Those links could be 
Figure 5: Estimated migration ﬂ uxes of individuals with HbS from Nigeria 
between 1960 and 2000
Thickness of the lines is proportional to the estimated number of HbS migrants 
to a given country. N=estimated number of net migrants with HbS. n=the 
number of countries to which individuals migrated. HbS=sickle-cell haemoglobin.
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developed to educate and prevent sickle-cell disorders in 
source countries, which would be of direct beneﬁ t to the 
sink countries, and to lessen the eﬀ ect of linguistic, 
cultural, and social barriers, which are usually associated 
with immigration in sink countries. For example, 
immigrants often tend to stay endogamous, and 
consanguineous marriages are common practice in 
various ethnic groups. Understanding of social 
Figure 6: Estimated migration ﬂ uxes of individuals with HbS to the USA and the UK from 1960 to 2000
The thickness of the lines is proportional to the proportion of HbS migrants from a speciﬁ c country amongst the total number of HbS immigrants. N=the estimated number of net migrants with HbS. 
n=the number of countries from which individuals migrated. HbS=sickle-cell haemoglobin.
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behaviours is therefore crucial in the prevention of these 
disorders.52–54 The research community has already 
started developing such a collaborative approach, as 
shown by the Global Sickle Cell Disease Network, which 
aims to bring together clinicians and researchers from all 
over the world to build a dynamic community focusing 
on a global health problem, increase awareness of sickle-
cell disorders, and improve the future of patients; 
however, similar oﬃ  cial collaborations supported by 
ministries of health, international health agencies, and 
major funding bodies have so far been scarce.55
The trends described in this study are also noted for 
many other mutations of the globin genes, including 
HbC, HbE, HbD, and numerous α-thalassaemia and 
β-thalassaemia variants, which should also be carefully 
considered. Many haemoglobin and thalassaemia 
variants have already been identiﬁ ed and, thanks to 
advances in genetics, new variants are still regularly 
being discovered.56 Larger and more diverse ﬂ uxes of 
migrants could result in the emergence of pairs of 
variants, which were previously highly unlikely to be co-
inherited because of the absence of overlap between 
their respective original geographical distributions, 
leading to an increasing complexity of genotypes and 
phenotypes potentially encountered by clinicians.57 
Increased awareness about known variants and their 
severity is crucial in the prevention of the most severe 
combinations.
Our study has several limitations. First, we assumed 
that the probability to emigrate is equal for any individual 
within a speciﬁ c country, and that this probability is 
independent of the ethnic origin or HbS genotype of a 
particular individual. This assumption is especially 
relevant in a country such as India in which the social 
structure is very complex and would certainly aﬀ ect the 
opportunities to migrate. In the absence of data for these 
parameters for migrants, a stochastic model-based 
approach could be developed to account for diﬀ erent 
likelihoods to migrate. Such an approach would also 
enable the generation of precision measures associated 
with the trends shown in this analysis. Second, the 
accuracy of the international migration database used 
here is unknown. A complex succession of techniques is 
used to standardise the data and to ﬁ ll in the gaps in 
space and time.31 Moreover, some oﬃ  cial migration data 
are based on random surveys (eg, the international 
passenger survey in the UK) and illegal migrations are 
not included. Nevertheless, no associated uncertainty 
measures are available. The uncertainties we report are 
therefore only associated with the HbS frequency 
estimates. Studies of global migration have only been 
undertaken recently1,2 and an increasing demand for 
reliable and comprehensive data might lead to the 
calculation of precision measures in future international 
migration databases.58,59 Third, this study focuses on only 
sickle haemoglobin; information about other 
haemoglobinopathies or birth defects would be needed 
to better assess the eﬀ ect of migrants on local public 
health services. Compound statuses like sickle-cell 
haemoglobin C disease or sickle-cell β thalassaemia also 
contribute to the burden of sickle haemoglobin. This 
limitation is partly due to our restricted knowledge of the 
contemporary distribution and prevalence of such 
compound statuses. Finally, whether the trends observed 
over the last half-century will continue in the coming 
years is unclear,60 and the implementation of speciﬁ c 
health interventions should be carefully considered. 
Studies have been published about the cost-eﬀ ectiveness 
of targeted versus universal screening programmes,43,61 
and this eﬀ ectiveness will depend on the individual 
context of each country. Nevertheless, increased 
awareness about this disorder and its wide distribution 
can only beneﬁ t patients and carriers.
This study provides further evidence of the fact that 
public health problems represent global issues that need 
to be addressed collectively by low-income and high-
income countries (panel).4,36 The likelihood of ﬁ nding 
diseases and genetic disorders that previously had a 
restricted distribution has increased in recent decades, 
and this trend is unlikely to change in the near future. 
Countries can adopt national measures, such as 
screening programmes, to reduce the local burden of 
such disorders, but in the long term, a concerted 
approach based on multinational collaborations and 
partnerships focusing on countries of high prevalence 
would probably be much more eﬀ ective;29 this approach 
is particularly relevant for sickle-cell disorders.
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Panel: Research in context
Systematic review
The search strategy and selection criteria have been previously described.32 Although 
various studies have described the eﬀ ects of globalisation and population movements 
from a social, cultural, economic, or political point of view, few have investigated the eﬀ ect 
of recent population movements on the distribution of human deleterious genes. Such 
migrations can have a profound eﬀ ect on the range and frequency of inherited disorders. 
Angastiniotis and colleagues studied the eﬀ ect of migrations on health services for rare 
diseases across Europe.10 In the specialty of haemoglobinopathies, various studies have 
been done investigating the eﬀ ect of migration on health-care services for patients with 
sickle-cell disease and thalassaemia in countries including the UK,61 the USA,14 Western 
Australia,62 Iran,63 and Italy.36 Nevertheless, the eﬀ ect of recent international migrations on 
the global distribution of the sickle-cell gene32 has not been investigated in detail.
Interpretation
To our knowledge, this study is the ﬁ rst to investigate the eﬀ ect of recent global migration 
on the distribution of a deleterious gene—the sickle-cell gene. The increase and 
diversiﬁ cation of migration ﬂ uxes and their eﬀ ect on health-care systems should be seriously 
considered when national and international health policies are deﬁ ned.
For the Global Sickle Cell 
Disease Network see http://
www.globalsicklecelldisease.org
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